Researchers tracked DNA from 30 patients with myeloproliferative neoplasms and found that genetic changes often preceded clinical progression by years. Patients with stable disease tended to have few DNA changes, while those who progressed showed new or expanding clones long before routine blood tests detected problems. Nine participants developed acute myeloid leukemia; three triple-negative essential thrombocythemia cases showed no cancer-associated mutations. The study suggests serial DNA testing could enable earlier monitoring, though larger studies are needed.
DNA Warning Signs Can Predict Blood Cancer Years Before Routine Tests, Study Finds
Patients whose disease remained stable often showed little genetic change over time, the researchers found.
New research suggests that patterns in a patient’s DNA can signal whether certain blood cancers are likely to progress years before routine blood tests detect changes. The study, published in Cancer Discovery by the American Association for Cancer Research, followed 30 people with myeloproliferative neoplasms (MPNs), a group of blood disorders in which the bone marrow makes too many blood cells.
Genetic changes sometimes emerged years before routine blood tests detected disease progression, the study found.
What The Researchers Did
Investigators repeatedly sequenced DNA from participants’ blood and bone marrow to identify genetic changes over time. They then compared those changes with clinical measures—blood counts, stable disease, and progression to myelofibrosis or acute myeloid leukemia (AML).
"This research shows that these blood cancers may reveal their future course in a person's DNA long before any symptoms appear, a genuinely exciting scientific insight, and a step toward precision medicine in blood cancer care," an expert said.
Key Findings
- Early Genetic Signals: Many patients who later progressed showed new DNA changes or emerging clones years before routine blood tests signaled disease progression.
- Genetically Quiet Disease: Patients with clinically stable MPNs generally exhibited little genetic change over time, suggesting a "genetically quiet" form of the disease that is less likely to advance.
- Varied Paths to Leukemia: Nine of the 30 participants developed AML. In some cases, AML evolved from the original MPN clone through accumulated mutations; in others, leukemia appeared to arise from a distinct clone of abnormal cells.
- Triple-Negative Cases: Three participants with triple-negative essential thrombocythemia (ET) showed no detectable cancer-associated mutations, raising the possibility that some people diagnosed with this condition may not have a malignant disease and might not require long-term cancer therapy.
- Drug-Associated DNA Signatures: The team detected characteristic small DNA changes linked to treatments: hydroxyurea (commonly used to control blood counts) and azacitidine. Importantly, the study found no evidence that hydroxyurea causes leukemia.
Clinical Implications
These findings indicate that periodic DNA monitoring could give clinicians an early warning that an MPN is trending toward a higher-risk state well before routine blood tests detect it. In the near term, this would most likely mean closer surveillance—more frequent blood counts and bone marrow checks—rather than immediate, aggressive interventions.
The next step, according to one doctor, would be pairing early genetic detection with drugs designed to act on those specific mutations, which could potentially prevent or delay disease progression.
“This research shows that these blood cancers may reveal their future course in a person’s DNA long before any symptoms appear,” said Abhishek Chilkulwar, an oncologist not involved in the study, underscoring the research as a step toward precision medicine in blood cancer care.
Limitations And Next Steps
The study is limited by a small sample size (30 patients) and reports associations rather than proof of cause and effect. Future research should validate these findings in larger, diverse populations and test whether early, targeted interventions based on DNA changes can prevent progression. Long-term goals include developing drugs that target high-risk mutations and integrating serial genomic testing into routine care.
Bottom line: DNA sequencing over time may provide an early heads-up about which MPN patients are likely to progress, enabling closer monitoring and, eventually, targeted preventive strategies—though clinical use will require further validation.
Help us improve.
